SCHEMBL86384

SCHEMBL86384

NCCCn1cnc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.72
SMN1; SMN2 Q16637 8/20 0.62
LMNA P02545 6/20 0.62
TSHR P16473 2/20 0.62
ALOX15 P16050 1/20 0.62
HTT P42858 5/20 0.60
MAPT P10636 4/20 0.57
RAB9A P51151 2/20 0.57
NPC1 O15118 1/20 0.57
NFKB1 P19838 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
EGLN3 Q9H6Z9 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
STAT3 P40763 1/20 0.56
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
DRD2 P14416 1/20 0.55
DRD4 P21917 1/20 0.55
DRD3 P35462 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6851027 0.95 TDP1 (0.70) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL8654324 0.93 TDP1 (0.68) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL825596 0.89 TDP1 (0.78) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL9814242 0.89 TDP1 (0.84) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL3161153 0.89 TDP1 (0.84) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL30294105 0.89 TDP1 (0.84) TDP1SMN1; SMN2LMNATSHRALOX15
Hydrochloric Acid SCHEMBL5864330 0.87 TDP1 (0.75) TDP1SMN1; SMN2LMNATSHRALOX15
Hydrochloric Acid SCHEMBL31547778 0.87 TDP1 (0.75) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL2331250 0.87 TDP1 (0.81) TDP1SMN1; SMN2LMNATSHRALOX15
SCHEMBL352046 0.87 TDP1 (0.81) TDP1SMN1; SMN2LMNATSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 US disclosed
CN-112004845-B Resin composition, laminate, semiconductor wafer with resin composition layer, substrate, and semiconductor device 三菱瓦斯化学株式会社 2022-05-31 CN disclosed
EP-3807264-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-04-21 EP disclosed
CN-112004845-A Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer, and semiconductor device 三菱瓦斯化学株式会社 2020-11-27 CN disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 WO disclosed
EP-2585498-B1 QUATERNIZED COPOLYMER BASF SE (DE) 2018-05-30 EP disclosed
EP-2082041-B1 NOVEL GENES RELATED TO GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2018-03-14 EP disclosed
US-8911516-B2 Quaternized copolymer BASF SE (DE) 2014-12-16 US disclosed
US-8809010-B2 Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases PROBIODRUG AG (DE) 2014-08-19 US disclosed
EP-0787711-A2 Process for the preparation of alpha,beta-unsaturated carboxylic acids F. HOFFMANN-LA ROCHE AG (CH) 1997-08-06 EP disclosed
EP-0730578-A1 INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) MERCK & CO. INC. (US) 1996-09-11 EP disclosed
WO-1995014666-A1 INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) MERCK & CO., INC. (US) 1995-06-01 WO disclosed
EP-0230035-B1 Omega-[(hetero)alkyl]benz[cd]indol-2-amines AMERICAN CYANAMID CO (US) 1994-10-12 EP disclosed
US-4728663-A HYPOTENSIVE, ANTIARRHYTHMIA AMERICAN CYANAMID COMPANY (US) 1988-03-01 US disclosed
EP-0230035-A2 Omega-[(hetero)alkyl]benz[cd]indol-2-amines AMERICAN CYANAMID COMPANY (US) 1987-07-29 EP disclosed
US-4434174-A Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines BERLEX LABORATORIES, INC. (US) 1984-02-28 US disclosed
US-4363808-A N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines BERLEX LABORATORIES, INC. (US) 1982-12-14 US disclosed
EP-0034116-A2 N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines BERLEX LABORATORIES, INC. (US) 1981-08-19 EP disclosed
US-4264494-A Chromium complex dyestuffs for natural polyamides and synthetic nylons BASF AKTIENGESELLSCHAFT (DE) 1981-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS TDP1 266/4885SMN1; SMN2 3753/4885LMNA 3267/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS TDP1 266/4885SMN1; SMN2 3753/4885LMNA 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.